Fiera Capital Corp trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 20.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,245 shares of the company’s stock after selling 1,600 shares during the period. Fiera Capital Corp’s holdings in Eli Lilly And Co were worth $723,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Athena Capital Advisors LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at $26,000. Larson Financial Group LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at $29,000. Ironwood Financial llc purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at $30,000. Acima Private Wealth LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at $33,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 77.00% of the company’s stock.

LLY has been the subject of several analyst reports. Barclays reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Eli Lilly And Co in a research note on Sunday, January 20th. BMO Capital Markets lifted their price objective on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a research note on Monday, December 24th. They noted that the move was a valuation call. JPMorgan Chase & Co. initiated coverage on shares of Eli Lilly And Co in a research note on Tuesday. They issued an “overweight” rating and a $140.00 price objective for the company. UBS Group initiated coverage on shares of Eli Lilly And Co in a research note on Wednesday, January 23rd. They issued a “buy” rating and a $131.00 price objective for the company. Finally, Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price objective for the company in a research note on Wednesday, November 28th. Eleven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Eli Lilly And Co currently has an average rating of “Buy” and an average target price of $113.06.

Eli Lilly And Co stock opened at $123.08 on Friday. The firm has a market cap of $127.87 billion, a price-to-earnings ratio of 22.18, a PEG ratio of 2.49 and a beta of 0.33. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $130.75.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm’s revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. Equities analysts forecast that Eli Lilly And Co will post 5.62 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, March 8th. Shareholders of record on Friday, February 15th were given a dividend of $0.645 per share. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date was Thursday, February 14th. This represents a $2.58 dividend on an annualized basis and a yield of 2.10%. Eli Lilly And Co’s payout ratio is currently 46.49%.

In other Eli Lilly And Co news, insider Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total transaction of $127,010.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 833,190 shares of company stock valued at $102,388,102. Company insiders own 0.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2019/03/15/eli-lilly-and-co-lly-shares-sold-by-fiera-capital-corp.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Rule of 72

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.